Roy Suryo
Chloe’s ordeal began when she was first diagnosed with HG during her initial pregnancy. Unaware of the condition’s severity, she found herself confined to bed for her entire first trimester, subsisting on ice cubes as she could neither eat nor drink. The sickness was so profound that her partner had to assist with basic personal care, including bathing her. Despite adjustments to her work duties, the birth of her son in 2023 brought the sickness to an end, but the psychological and physical toll remained.
The unexpected second pregnancy brought immediate distress. "I remember when I found out I literally turned around to my partner and I was like, ‘what do we do?’" she recounted. The severe nausea and vomiting returned, exacerbating her mental health struggles. She was unable to take her prescribed antidepressants due to the sickness, leading to a significant decline in her well-being. The situation escalated to the point where she booked an abortion, expressing her profound fear for her own safety.
A crucial turning point came during an ectopic pregnancy scare, which led her to consult a gynaecologist. This specialist was able to prescribe Xonvea, an anti-sickness medication that has been instrumental in managing her symptoms. Xonvea is recommended by the Royal College of Obstetricians and Gynaecologists as an effective first-line treatment for HG, alongside other medications like cyclizine, prochlorperazine, and ondansetron. However, Xonvea is not routinely available in Wales, despite its higher cost of £28.50 for a box of 20 tablets compared to other alternatives. It is only prescribed when other treatments have failed. Recent data indicates that Xonvea is prescribed by a significant number of GP practices, with 223 prescriptions issued by 103 practices in October alone.
The availability of Xonvea proved life-changing for Chloe, allowing her to cancel her planned termination. "At the start, it just meant that I was able to take my antidepressants, which then helped level my mood. I was able to eat a little piece of toast. And then as time went on and my hormones started to settle, I was then able to eat a proper meal," she explained. This relief, however, has not diminished her desire to prevent future pregnancies. Chloe is now in the process of arranging sterilisation, stating that she is unable to face the prospect of another pregnancy.
Hyperemesis gravidarum affects a significant minority of pregnant women. According to NHS Wales, approximately one to three in every 100 pregnant women experience HG, though the actual number may be higher due to underreporting. The symptoms are severe and can include intense nausea, vomiting, significant dehydration, and substantial weight loss, frequently necessitating hospitalisation and intensive medical intervention.
Dr. Georgina Forbes, a specialist in sexual and reproductive health and chair of the College of Sexual and Reproductive Healthcare’s Wales committee, shared her personal and professional insights into the devastating impact of HG. She highlighted that many women seeking abortions had struggled to access effective treatments like Xonvea, arriving at her clinic "entirely at their wits’ end. They are broken." Dr. Forbes strongly advocates for the Welsh government to reconsider its stance on Xonvea, arguing that its cost is negligible when compared to the financial burden of hospitalisation and repeated medical treatments associated with severe HG. She pointed out that the cost of hospital stays, including intravenous fluids and other medications, far outweighs the price of a box of Xonvea, making its routine availability a sound investment in healthcare.
Plaid Cymru MS Lindsay Whittle has also been a vocal advocate for improved access to Xonvea in Wales. He has received numerous "heart-wrenching" accounts from constituents living with HG and has supported campaigns for better drug access through his role on the Senedd’s petitions committee. Mr. Whittle emphasised the relatively low cost of Xonvea, comparing it to the price of an average meal out, and questioned the rationale for withholding such an essential medication. He expressed a desire for the Welsh government to prioritise patient well-being over such minor financial considerations.
In response to these concerns, the Welsh government stated that GPs across all health board areas in Wales do prescribe Xonvea. They rely on independent advice from bodies like the National Institute for Health and Care Excellence (NICE) and the All-Wales Medicines Strategy Group (AWMSG) for the routine availability of medicines on the NHS. The government spokesperson explained that the AWMSG’s appraisal, the most current formal evaluation of Xonvea in Wales in the absence of NICE guidance, did not recommend its routine use due to insufficient cost-effectiveness data. However, the AWMSG has indicated that it has been in "proactive engagement with the manufacturer for over 18 months and are actively exploring the options available to them." The continued debate over Xonvea’s accessibility underscores the critical need for adequate support and treatment options for women suffering from hyperemesis gravidarum, ensuring that debilitating conditions do not force such difficult choices upon them. Chloe’s decision to seek sterilisation is a stark testament to the profound and lasting impact of severe pregnancy sickness, highlighting the urgent need for comprehensive care and readily available treatments for women in Wales.
Ramos Leo
Nakalama John
George Anjay
